Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist ...
SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results